You are here: Industry Insights > Lartruvo

News List

Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market drugs
May 09, 2019
Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market.
Lilly to withdraw cancer drug Lartruvo from global market pharmaceutical-technology
April 28, 2019
Eli Lilly has announced an access programme for patients that wish to continue using its cancer drug Lartruvo (olaratumab) as the company prepares to withdraw the medication from markets worldwide.
Lilly to withdraw cancer drug Lartruvo from global market pharmaceutical-technology
April 28, 2019
Eli Lilly has announced an access programme for patients that wish to continue using its cancer drug Lartruvo (olaratumab) as the company prepares to withdraw the medication from markets worldwide.
Lilly's tarnished Lartruvo faces uncertain future after FDA red-flags new patient starts fiercepharma
January 28, 2019
That was fast. Within a week of a surprise trial failure for Eli Lilly’s soft tissue sarcoma drug Lartruvo, regulators on both sides of the Atlantic have warned doctors not to start new patients on the drug.
Cancer drug with accelerated approval fails Phase III trial europeanpharmaceuticalreview
January 24, 2019
Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone…
Lilly Reports LARTRUVO Study Did Not Meet Primary Endpoint americanpharmaceuticalreview
January 23, 2019
Eli Lilly and Company reported the results of ANNOUNCE, the Phase 3 study of LARTRUVO (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS)....
Lilly reports results of ANNOUNCE biospectrumasia
January 22, 2019
As ANNOUNCE did not confirm clinical benefit, Lilly is working with global regulators to determine the appropriate next steps for LARTRUVO
Lilly stops promoting cancer drug after shock trial failure pharmaphorum
January 22, 2019
Shares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo failed to meet main survival goals in a late stage trial, prompting the company to stop promoting the already-marketed medicine.